Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Shares Outstanding (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Shares Outstanding for 12 consecutive years, with $194.0 as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding fell 99.99% to $194.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $194.0, a 99.99% decrease, with the full-year FY2025 number at $194.0, changed 0.0% from a year prior.
  • Shares Outstanding was $194.0 for Q4 2025 at Iovance Biotherapeutics, down from $1.9 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $279.8 million in Q1 2024 to a low of $194.0 in Q3 2024.
  • A 3-year average of $46.1 million and a median of $2.4 million in 2023 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: skyrocketed 10360.57% in 2024, then tumbled 99.99% in 2025.
  • Iovance Biotherapeutics' Shares Outstanding stood at $256.1 million in 2023, then crashed by 98.89% to $2.8 million in 2024, then crashed by 99.99% to $194.0 in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Shares Outstanding are $194.0 (Q4 2025), $1.9 million (Q3 2025), and $341.9 million (Q2 2025).